



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 38/28, 39/00, 38/46, 38/51	A1	(11) International Publication Number: WO 98/14203 (43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/AU97/00654 (22) International Filing Date: 1 October 1997 (01.10.97) (30) Priority Data: PO 2699 1 October 1996 (01.10.96) AU (71) Applicant (for all designated States except US): AMRAD OPERATIONS PTY. LTD. [AU/AU]; 576 Swan Street, Richmond, VIC 3121 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): HARRISON, Leonard, Charles [AU/AU]; 27 Park Street, St. Kilda West, VIC 3182 (AU). DEMPSEY-COLLIER, Majella [AU/AU]; 279 Nicholson Street, East Brunswick, VIC 3057 (AU). (74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A METHOD AND COMPOSITIONS FOR TREATMENT OF INSULIN-DEPENDANT DIABETES MELLITUS (57) Abstract <p>The present invention relates generally to a method of prophylaxis and treatment of autoimmune disease conditions and agents useful for same. More particularly, the present invention contemplates mucosa-mediated tolerance to protect against or ameliorate the symptoms associated with autoimmune pathology. Even more particularly, the present invention provides a method for preventing clinical diabetes or preventing or reducing or ameliorating the effects of clinical diabetes by the aerosol administration of diabetes-associated autoantigens to mucosal surfaces.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A METHOD AND COMPOSITIONS FOR TREATMENT OF INSULIN-DEPENDANT DIABETES MELLITUS

The present invention relates generally to a method of prophylaxis and treatment of
5 autoimmune disease conditions and agents useful for same. More particularly, the present
invention contemplates mucosa-mediated tolerance to protect against or ameliorate the
symptoms associated with autoimmune pathology. Even more particularly, the present
invention provides a method for preventing clinical insulin-dependent diabetes mellitus
(IDDM) or preventing or reducing or ameliorating the effects of clinical IDDM by the
10 aerosol administration of IDDM-associated autoantigens to mucosal surfaces.

Bibliographic details of the publications numerically referred to in this specification are
collected at the end of the description.

15 Throughout this specification and the claims which follow, unless the context requires
otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be
understood to imply the inclusion of a stated integer or group of integers but not the
exclusion of any other integer or group of integers.

20 The increasing knowledge of the immune system in general and cellular immune
mechanisms in particular is greatly facilitating the design of therapeutic agents and
alternative routes of their administration. One important area of research is the
mechanisms underlying cellular immune hyporesponsiveness induced by particular
antigens in autoimmune disease conditions.

25

An autoantigen can be assumed to be pathogenic if its administration modifies the natural
history of autoimmune disease. Autoantigen-specific strategies of immune tolerance
induction have been shown to favourably modify the natural history of experimental
autoimmune disease in rodents (8, 24-28). The presentation of soluble protein antigen to
30 mucosal surfaces, classically via the oral route, results in selective suppression of antigen-

- 2 -

specific T cell-mediated, delayed-type hypersensitivity (DTH) and IgE responses (2, 8, 29). 'Oral tolerance' has been associated with deviation of immunity away from T-cell (Th1) to antibody (Th2) responses, with the induction of regulatory T cells and, at higher antigen doses, with both T-cell anergy and T-cell deletion (8, 30).

5

A particularly debilitating autoimmune condition is insulin-dependent diabetes mellitus (IDDM) which results from the selective destruction of insulin-producing β cells in the islets of the pancreas, within an autoimmune inflammatory 'insulitis' lesion (10, 11). The primary role of autoreactive T cells in mediating β -cell destruction has been shown
10 directly in two spontaneous animal models of IDDM, the Bio-Breeding (BB) (31) rat and the non-obese diabetic (NOD) mouse (24). Target autoantigens that trigger or drive immune reactivity to β cells not only have diagnostic applications but are potential agents for specific immunotherapy (25-28). Several potentially pathogenic islet/ β -cell
15 autoantigens have been identified by their reactivity with circulating antibodies or T cells in rodents and humans with sub-clinical or clinical IDDM, in particular insulin, glutamic acid decarboxylase (GAD) and tyrosine phosphatases of the IA-2 family (32). However, insulin and its precursor, pre-proinsulin, are the only IDDM autoantigens that are β -cell specific.

20 Insulin autoantibodies (IAA) are a risk marker for the development of clinical IDDM (33) and have been detected before autoantibodies to other islet antigens in the offspring of diabetic mothers (34). Increased proliferation of peripheral blood T cells to human insulin can be demonstrated in up to half of sub-clinical and recently-diagnosed IDDM subjects (35), but responses are relatively low. This is possibly because the dominant human T-
25 cell epitope is in proinsulin. A peptide that spans the natural cleavage site between the B chain of insulin and the connecting (C) peptide in proinsulin was reported to elicit T-cell proliferation in a majority of at-risk IDDM relatives (36). In the NOD mouse, IAA are reported to be a risk marker for the development of diabetes (37) and the majority of T-cell clones generated from the insulitis lesion reacted to insulin B-chain, amino acids 9-23
30 (38).

- 3 -

Despite widespread interest in the possibility of preventing IDDM, relatively few studies have evaluated mucosa-mediated tolerance in the natural NOD mouse model. Zhang *et al.* (22) found that oral porcine insulin (1mg twice weekly) delayed the onset and reduced the incidence of diabetes, and was associated with splenic T cells that partially blocked the transfer of diabetes to young, non-diabetic mice by spleen cells from diabetic mice. Subsequently, Bergerot *et al.* (23) reported that the regulatory cells induced by oral insulin were CD4+ T cells. However, in studies of oral tolerance to guinea pig myelin basic protein (MBP) in the Lewis rat model of experimental autoimmune encephalomyelitis (EAE) (8), both CD4 and CD8 regulatory T cells which secrete IL-4, IL-10 and TGF- β have been described.

There is a need to develop effective administration strategies for delivery of antigens to induce suppression of cell-mediated autoimmune conditions. The administration strategies must not only to be immunologically effective but also convenient, direct and safe for the user. In work leading up to the present invention, the inventors investigated the aerosol administration of insulin and its precursors in an animal model for IDDM and showed that this was effective in reducing pancreatic islet pathology and incidence of diabetes.

Accordingly, one aspect of the present invention contemplates a method of suppressing a cell-mediated autoimmune disease in a subject, said method comprising the administration as an aerosol of an effective amount of an antigen associated with said autoimmune disease for a time and under conditions sufficient to prevent, reduce or otherwise ameliorate autoimmune pathology.

More particularly, the present invention provides a method of preventing, reducing or otherwise ameliorating an autoimmune disease condition in a subject, said method comprising the administration, as an aerosol, to said subject of an effective amount of an antigen associated with said autoimmune disease for a time and under conditions sufficient to induce or stimulate immunoregulatory mechanisms which are protective against cell-mediated autoimmune pathology.

- 4 -

Reference hereinafter to "immunoregulatory mechanisms" should be understood as a reference to all mechanisms which regulate cell-mediated immune responses including, but not limited to, regulation of T cell functional activity, for example regulation of one or more of suppressor T cells, Th1, Th2 or CD8⁺ T cells (referred to herein as "regulatory T
5 cells"), or via regulation of cytokine production by lymphoid, myeloid or stromal cells.

The present invention is hereinafter described with respect to preventing, reducing or otherwise ameliorating IDDM, slowly progressive IDDM (SPIDDM) also referred to as latent autoimmune diabetes in adults [LADA] and gestational diabetes due to underlying
10 IDDM. This is done, however, with the understanding that the present invention extends to a range of cell-mediated autoimmune conditions.

Accordingly, another aspect of the present invention contemplates a method of preventing, reducing or otherwise ameliorating IDDM, SPIDDM or gestational diabetes in a subject,
15 said method comprising the administration, as an aerosol, to said subject of an effective amount of an autoantigen associated with IDDM for a time and under conditions sufficient for induction of regulatory T-cells and/or other suitable mechanisms sufficient to suppress cell-mediated autoimmune pathology associated with IDDM.

20 Reference hereinafter to "IDDM" includes IDDM, SPIDDM and gestational IDDM.

The regulatory T cells induced will depend on the form of antigen and its route of administration. For example, when a long peptide or whole molecule is administered (eg. insulin), CD8 T cells and, more particularly, CD8 $\gamma\delta$ T cells are induced. Smaller
25 molecules such as proinsulin peptides (eg. proinsulin peptide 24-36) generally induce CD4 T cells and, more particularly, CD4 $\alpha\beta$ T cells.

A particularly preferred form of administration is intranasal administration *via* an aerosol spray, drip or vapour.

- 5 -

The preferred antigen associated with IDDM used for aerosol or other intranasal administration composition is preproinsulin or proinsulin as well as insulin and their immune response stimulatory derivatives thereof such as but not limited to peptide fragments of proinsulin, (eg. proinsulin peptide 24-36), preproinsulin or insulin. Immune
5 response stimulation preferably includes regulatory T cell stimulation. However, any islet antigen may be employed such as, but not limited to, glutamic acid decarboxylase (GAD) in its various isoforms (for example GAD 65 and GAD 67) or derivatives thereof and tyrosine phosphatase IA-2 or derivatives thereof. Said antigens may be from human or any non-human species such as mouse.

10

The term "derivatives" includes fragments, parts, portions, chemical equivalents, mutants, homologs and analogs of the antigens. Analogs may be derived from natural synthetic or recombinant sources and include fusion proteins. Chemical equivalents of an antigen can act as a functional analog of an antigen. Chemical equivalents may not necessarily be
15 derived from an antigen but may share certain conformational similarities. Alternatively chemical equivalents may be specifically designed to mimic certain physiochemical properties of an antigen. Chemical equivalents may be chemically synthesised or may be detected following, for example, natural product screenings.

20 A homolog of an antigen contemplated herein includes but is not necessarily limited to antigens derived from human or any non-human species such as mouse.

Derivatives include one or more insertions, deletions or substitutions of amino acids. Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as
25 well as intrasequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in said cytokines although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more amino acids from the sequence. Substitutional amino acid variants
30 are those in which at least one residue in the sequence has been removed and a different

- 6 -

residue inserted in its place. Additions to amino acid sequences include fusions with other peptides or polypeptides. It is possible, for example, that the subject preferred cytokines may be substituted by other cytokines or lymphoid cytokines or functional homologs or analogs. A hybrid cytokine may comprise a combination of cytokines.

5

Said derivatives include peptide derivatives and peptide epitope analogs. Reference to a "disease suppressing peptide comprising proinsulin 24-36 sequence" should be understood to include reference to a proinsulin 24-36 sequence to which flanking amino acid sequences have been added to one or both ends of said proinsulin 24-36 sequence. Said
10 flanking ends may be useful, for example, for enhancing the effectiveness of the proinsulin 24-36 sequence by a mechanism such as increasing the hydrogen bonding of said proinsulin 24-26 sequence to MHC molecules. Said flanking ends may comprise, for example, alanine residues which are added to the C terminus of said proinsulin 24-36 sequence.

15

The term "aerosol" is used in its most general sense to include any formulation capable of administration *via* nasal, pharyngeal, bronchial or oral passages. Aerosols generally comprise particles of liquid or solid suspended in a gas or vapour. Conveniently, the aerosol is a colloidal system such as a mist in which the dispersion medium is a gas. The
20 method of administering the aerosol formulation is not critical and may be achieved using a hand pump, electric pump, pressurised dispenser, nasal drip or other convenient means. It should be understood that the method of the present invention extends to direct application of said formulations to intranasal surfaces. In a particularly preferred embodiment, the aerosol is delivered at a rate of from about 1 to about 20 litres/min. and
25 preferably from about 2 to about 15 litres/min. at a droplet size of from about 0.1 to about 10 μm and more preferably from about 0.1 to about 6 μm . Conveniently, a stock solution of antigen is prepared at a concentration of from about 0.5 to about 20 mg/ml or more preferably from about 1.0 to about 10 mg/ml of carrier solution. Commercially available insulin is particularly useful which is about 4 mg/ml. A useful dose is from about 50 μl to
30 1000 μl and preferably 100 μl to 500 μl from the stock solution.

- 7 -

The antigen may be administered alone or by formulation in or with an adjuvant. The adjuvant is selected from a range of adjuvants which enhance an immunoregulatory response including cholera toxin B, heat labile toxin of *E. coli*, saponin, Quill A extracts and other derivatives of saponin, DEAE-dextran, dextran sulphate, aluminium salts, and
5 nonionic block co-polymers. The adjuvant may include other immunomodulators, such as cytokines (for example IL-4 or IL-13), muramyl-dipeptide and derivatives, and cell wall components from species of mycobacteria or corynebacteria. The adjuvant formulation may include a combination of two or more of the adjuvants listed. These lists are not to be taken as exhaustive. The selection of adjuvant is in part dependent on the species being
10 targeted and is based on the level and duration of the immune response required and on the lack of reactogenicity (ie tissue compatibility). The level of active component and adjuvant are chosen to achieve the desired level and duration of immune response.

The antigen is administered in a therapeutically effective amount. A therapeutically
15 effective amount means that amount necessary at least partly to attain the desired effect, or to delay the onset of, inhibit the progression of, or halt altogether, the onset or progression of the particular condition being treated. Such amounts will depend, of course, on the particular conditions being treated, the severity of the condition and individual patient parameters including age, physical conditions, size, weight and
20 concurrent treatment. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgement. It will be understood by those of ordinary skill in the art, however, that a lower dose or tolerable dose may be administered for medical reasons, psychological
25 reasons or for virtually any other reasons.

Generally, daily oral doses of antigen will be from about 0.01 mg/kg per day to 1000 mg/kg per day. Small doses (0.01-1 mg) may be administered initially, followed by increasing doses up to about 1000 mg/kg per day. In the event that the response in a
30 subject is insufficient at such doses, even higher doses (or effective higher doses by a

- 8 -

different, more localised delivery route) may be employed to the extent patient tolerance permits. A single dose may be administered or multiple doses may be required on an hourly, daily, weekly or monthly basis. Effective amounts of antigen vary depending on the individual but may range from about 0.1 μg to about 20 mg, preferably from about 1 μg to about 10 mg and more preferably from about 1 μg to 5 mg per dose.

In a related aspect of the present invention the subject undergoing treatment may be any human or animal in need of therapeutic or prophylactic treatment.

- 10 The immune status generally, and specifically levels of regulatory T cells and cytokine profiles, may be readily determined throughout any treatment regime using conventional methods known to those skilled in the art. For example, regulatory T cell levels may be monitored by cytometric analysis following labelling with commercially available antibodies specific to T cell subsets. Other examples of methods suitable for determining
- 15 the status of the subject include purification of peripheral blood mononuclear cells by density centrifugation followed by stimulation by incubation with well known antigens such GAD, IA-2 family members, insulin or proinsulin. Resulting proliferation may be quantified by assaying for incorporation of H^3 thymidine. The cytokine profile can be determined approximately 24 hours after stimulation by antigen. Said cytokines can be
- 20 detected using, for example, specific cytokine antibodies. 24 hours after stimulation with antigen, stimulated cells can be phenotypically characterised by, for example, flow cytometric analysis of activation marker expression (for example CD69, CD44, CTLA4, CD25). Following cell surface labelling of activated cells, said cells may be further fixed and incubated with fluorochrome labelled antibodies to specific cytokines to determine
- 25 intracellular cytokine levels. In particular, for example, cells may be further assessed by double labelling assays. The double labelled cells may be analysed utilising flow cytometric analysis or fluorescence spectroscopy.

Another aspect of the present invention provides a composition comprising an antigen

30 associated with an autoimmune disease in an aerosol formulation including one or more

- 9 -

pharmaceutically acceptable carriers and/or diluents.

Preferably, the autoimmune disease is IDDM.

- 5 Preferably, the antigen is an islet antigen such as insulin, or a precursor thereof such as preproinsulin, proinsulin or their derivatives (eg. proinsulin peptide 24-36) or GAD or tyrosine phosphatases IA-2 or derivatives thereof.

Preferably, the antigen and route of administration induce regulatory T cells, such as in
10 relation to whole molecules such as insulin CD8 T cells and most preferably CD8 $\gamma\delta$ T cells or, in relation to smaller molecules such as proinsulin peptide 24-36, CD4 T cells and most preferably CD4 $\alpha\beta$ T cells.

The present invention is further described by the following non-limiting Figures and/or
15 Examples.

In the Figures:

Figure 4 is a graphical representation showing that aerosol insulin induces CD8 T
20 cells that suppress transfer of diabetes. NOD male mice (n=16/group) aged 6-9 weeks were injected with pooled splenocytes from recently-diabetic 14-19 week old females, together with either unfractionated (A) or fractionated (B-E) splenocytes from aerosol insulin- or ovalbumin-treated NOD females, and their incidence of diabetes subsequently monitored. In
25 the experiment shown, aerosol donor mice had been treated for 10 consecutive days and then weekly from 49 days of age and were normoglycemic when sacrificed at 156 days of age.

Figure 5 is a graphical representation showing that aerosol insulin induces CD8 $\gamma\delta$ T
30 cells that suppress transfer of diabetes. Young male NOD mice were co-

- 10 -

5 injected with 'diabetic' splenocytes (2×10^7) and total or fractionated splenic T cells from aerosol-treated mice, as in the legend to Fig. 1. The numbers of fractionated cells injected were, in A) $\sim 10^7$ total T cells and, from aerosol insulin mice, $\sim 10^7$ $\gamma\delta$ -depleted T cells or 1.4×10^5 $\gamma\delta$ T cells and, in B), from aerosol insulin mice, $\sim 10^7$ total T cells, 2×10^6 CD8 T cells, 2×10^6 $\gamma\delta$ -depleted CD8 T cells or 1.5×10^5 CD8 $\gamma\delta$ +ve T cells.

10 **Figure 6** is a diagrammatical representation showing that adoptive transfer of diabetes is suppressed by CD8 $\gamma\delta$ T cells induced by aerosol insulin: summary of 11 experiments.

- 11 -

EXAMPLE 1**Aerosol treatment and diabetes assessment**

Semi-sealed boxes of eight female NOD mice were each aerosolized by connection to a standard, patient electric pump (Maymed Aerosol MKV, Anaesthetic Supplies, Sydney, Australia) and Acroflo nebulizer (Waite & Co., Sydney). Recombinant human insulin (Humulin R, Eli Lilly) or control ovalbumin protein, at 4mg/ml, was delivered over 10 min. at an air flow rate of 6 litres/min. in a rated droplet size of $< 5.8 \mu\text{m}$, to groups of 24-32 mice. All treatments were given between 0900 and 1100 hours. Protocols and mouse care were approved and supervised by the institutional Animal Ethic Committee. Retro-orbital venous blood was sampled at least every 28 days from 100 days of age and mice considered to be diabetic if their blood glucose, confirmed by a repeat test, was $> 11 \text{ mM}$. Glucose was measured with BM-Test Glycemic® strips and a Reflolux® II meter (Boehringer-Mannheim), on a drop of blood aspirated via a glass capillary tube from the retro-orbital venous plexus of unanesthetised mice.

EXAMPLE 2**Histology**

Mice were killed by CO_2 inhalation and the pancreas and salivary glands immediately removed into Bouin's fixative and embedded in paraffin. The insulitis score, a measure of the severity of islet infiltration was determined blindly by two independent investigators by grading and then averaging a minimum of 15 separate islets in serial $6 \mu\text{m}$ pancreas sections stained with haematoxylin and eosin. The grading scale was: 0, no filtration, islet intact; 1, < 10 peri-islet lymphoid cells, islet intact; 2, 10-20 peri- and intra-islet lymphoid cells, islet intact; 3, > 20 peri- and intra-islet lymphoid cells, $< 50\%$ of islet replaced or destroyed; 4, massive lymphoid infiltrate with $> 50\%$ of islet replaced or destroyed. Infiltration of the salivary glands was graded by the number of lymphoid cells in clusters: 0, no cells; 1, < 10 cells; 2, 10-50 cells; 3, > 50 cells.

- 12 -

EXAMPLE 3**Immune responses**

Spleen cells from individual normoglycemic mice were treated with a red cell lysis buffer, resuspended and incubated in quadruplicate at $2 \times 10^5 / 200 \mu\text{l}$ of serum-free HL-1 medium (Hycor, Irvine, CA) containing $50 \mu\text{M}$ 2-mercaptoethanol, in round-bottom wells with the indicated concentrations of antigen. After 3 days at 37°C in 5% v/v CO_2 /air, $100 \mu\text{l}$ aliquots from each replicate supernatant were collected and stored at -70°C for cytokine assays; the cells were then pulsed with 3H-thymidine, harvested 16 hours later and counted on a TopcountTM micro-scintillation counter (Packard, Meriden, CT). Insulin was recombinant human (Humulin R, Eli Lilly), as used for aerosol treatments. Insulin B-chain peptide corresponding to amino acids 9-23 of mouse insulin II (Peptide Express, Fort Collins, CO) was more than 90% pure by HPLC analysis. GAD65 was the recombinant human form expressed with a C-terminal hexahistidine in a baculovirus system and purified by Ni^{2+} chelation affinity chromatography. It was resolved as a single band in SDS-PAGE and was endotoxin-free by the quantitative Limulus lysate assay (BioWhittaker, Walkersville, MD).

IL-2, -4, -10 and IFN- γ were measured by ELISAs with monoclonal antibody pairs (Pharmingen); the lower limits of detection were 62, 16, 16 and 55pg/ml, respectively. TGF- β 1 was measured with an ELISA kit (Promega) with a lower limit of detection of 16pg/ml.

To detect insulin antibodies, ^{125}I -labelled human insulin (approx. 100,000 cpm: specific activity $120 \mu\text{Ci}/\mu\text{g}$) was incubated with or without excess unlabelled insulin ($10 \mu\text{g}/\text{ml}$) in phosphate-buffered saline containing a mixture of protease inhibitors and serial log dilutions of mouse serum, for 5 days at 4°C . Complexes were then precipitated with rabbit anti-mouse globulin anti-serum, washed and counted in a gamma counter. Positive control sera (guinea pig anti-porcine insulin serum, human IDDM sera) maximally precipitated 37-54% of the total radioactivity. Non-specific binding, in the presence of excess unlabelled insulin, was $\leq 3.3\%$.

- 13 -

EXAMPLE 4**Adoptive transfer of diabetes**

Male NOD mice aged 6-9 weeks (16/group) were irradiated (800R) from a Cobalt source
5 and 3-6 hours later received 2×10^7 pooled splenocytes from recently-diabetic 14-19
week-old female NOD mice, together with 2×10^7 splenocytes (or cells fractionated from
this number) from either aerosol insulin- or ovalbumin-treated mice, in 200 μ l via the tail
vein. The onset of diabetes was then monitored by measuring blood glucose starting two
weeks after transfer.

10

EXAMPLE 5**Fractionation of spleen cell populations**

Spleen cells were treated with red cell lysis buffer and resuspended in mouse tonicity
15 phosphate buffered saline. Total T cells were purified by non-adherence to nylon wool.
CD4 and CD8 cells were positively selected/depleted magnetically with monoclonal
antibodies directly bound to MACS MicroBeads (Milteny Biotec, GmbH, F.R.G.)
according to the manufacturer's protocols, and counted as viable cells (trypan blue stain
negative). Flow cytometry revealed 95% depletion of CD4 or CD8 cells, with recoveries
20 ~80% and ~50% respectively.

$\gamma\delta$ T cells were positively selected/depleted by incubating T cells from aerosol-treated
mice first with biotinylated GL3-1A antibody (Pharmingen, San Diego, CA) and then with
streptavidin-MACS MicroBeads, followed by magnetic separation. By flow cytometry,
25 $\gamma\delta$ cells comprised 1-2% of NOD splenocytes and were totally depleted with GL3-1A
antibody. To purify CD8 $\gamma\delta$ T cells, CD8 T cells were first magnetically selected from
total T cells with anti-CD8-FITC conjugate and anti-FITC MicroBeads. The MicroBeads
were then released according to the Miltenyi Biotec protocol, and the CD8 cells
magnetically separated into $\gamma\delta$ positive and depleted fractions. Double staining and FACS
30 analysis demonstrated total depletion of $\gamma\delta$ cells and their recovery as a GL3-1A high and
low expressing CD8 population.

- 14 -

EXAMPLE 6

Diabetes and insulinitis

Aerosol human insulin or ovalbumin were administered in different schedules to female
5 NOD mice from 28 days of age, the earliest time at which insulinitis is detectable in the
colony of mice, and their incidence of diabetes and severity of insulinitis subsequently
measured.

The incidence of diabetes was only marginally affected by a single aerosol insulin
10 treatment at 28 days of age, being 75% by 240 days of age compared to 88% after aerosol
ovalbumin. However, treatment for 3 or 10 consecutive days and then weekly
significantly delayed the onset and reduced the incidence of diabetes. In five separate
experiments, diabetes incidence at 156 days of age was reduced from a median of 47% in
ovalbumin-treated mice to 23% in insulin-treated mice; at 240 days of age, when the
15 cumulative incidence of diabetes approaches a maximum, the values were 79% and 49%,
respectively ($p=0.005$, Kaplan-Meier survival statistic). There was no difference if the
initial treatment was for 3 or 10 days. In another experiment, in which treatment was
given for 10 consecutive days and then weekly, but not started until 49 days of age when
insulinitis was well-established, aerosol insulin still significantly reduced diabetes incidence
20 at 156 days from 58% to 25% ($p=0.001$). Insulin treatment was associated with a
significant reduction in the severity of the islet lesion, as judged by the 'insulinitis score',
which paralleled the decrease in diabetes incidence (Table 1). Infiltration of the salivary
glands by lymphoid cells (sialitis), which also occurs in NOD mice, was unaffected by
aerosol insulin.

25

In the absence of absorption-promoting agents, systemic uptake of insulin from the naso-
pharyngeal mucosa in humans is insignificant (1). In NOD mice, blood glucose was not

- 15 -

altered in the short-term by aerosol insulin. Insulin solutions labelled with 10% Evan's Blue dye were observed to be deposited in the naso-pharynx, trachea and main bronchial divisions, as well as the oesophagus. While it may be difficult, if not impossible, to avoid some gastrointestinal exposure after aerosol or intranasal delivery of soluble protein,
5 delivery into the naso-pharynx alone is sufficient to induce tolerance (2, 3, 4).

EXAMPLE 7

Immune responses

10 The inventors investigated if aerosol insulin treatment had altered immune responses to insulin. Unprimed T-cell proliferative responses to islet antigens, including insulin, have been reported in NOD mice (5) but have not always been reproducible (6). Proliferative responses of spleen cells ($0.5-2.5 \times 10^6/\text{ml}$) from either insulin or ovalbumin-treated mice, aged 56-105 days, to human insulin or ovalbumin (0.2, 2.0, 20 and $40\mu\text{g}/\text{ml}$), in different
15 serum-supplemented or serum-free media varied by less than two-fold above basal and were usually depressed below basal at the highest concentration of insulin. Insulin at high concentrations has been reported to inhibit T-cell responses (7). In contrast, in the ovalbumin-treated control mice but not the insulin-treated mice, responses to insulin B-chain peptide a 9-23, a dominant epitope for NOD mouse islet-derived T-cell clones (38),
20 were significant (Table 2). Furthermore, ovalbumin mice had significantly higher responses than insulin mice to human glutamic acid decarboxylase 65 (GAD65), previously reported to stimulate splenic T cells in NOD mice (5). In mice from both treatment groups, proliferative responses to non-antigen-specific stimulation by concanavalin A or T-cell receptor CD3 monoclonal antibody, 145-2C11, were similar
25 (Table 2) and no different to untreated mice, indicating that aerosol treatment did not cause general immunosuppression. IL-2, IFN- γ and TGF- β 1 secretion in response to insulin B chain 9-23 were not significantly different between insulin- and ovalbumin-treated mice; however, the levels of IL-4 and particularly IL-10 were higher from cells of insulin-treated mice (Table 3).

- 16 -

Insulin antibodies were measured by a standard immunoprecipitation assay with sera (n=12/group) from insulin- and ovalbumin-treated mice aged 70-105 days. Precipitation of ^{125}I -insulin radioactivity by antibodies in sera from insulin-treated mice ($12.7 \pm 3.6\%$; mean precipitated cpm \pm SD) was significantly higher ($p < 0.01$, Mann Whitney U test) than in ovalbumin-treated mice ($6.9 \pm 2.5\%$). This increase in the 'level' of insulin antibodies after aerosol insulin, together with the suppression of T-cell proliferation and the increase in IL-4 and IL-10 responses to insulin B-chain peptide, is consistent with the phenomenon of immune deviation, as described after oral MBP in Lewis rats (8) and intranasal GAD peptides in NOD mice (9). β -cell destruction within the DTH lesion of

10 IDDM is an example of Th1-mediated process (10, 11), whose inhibition by aerosol insulin might be expected to shift the Th1/Th2 balance towards Th2 in response to key islet antigens. Defective suppressor T-cell function has been postulated to shift the balance towards Th1 in IDDM (11). It seems unlikely that the reduced T-cell proliferative response to GAD could reflect 'bystander' suppression due to the secretion of the Th2

15 cytokines IL4 and IL-10 (8) by insulin aerosol-induced regulatory cells because, apart from an absence of added insulin in the cultures with GAD, responses to conA and anti-CD3 were not impaired. A direct explanation is that the reduced response to GAD reflects the protective effect of aerosol insulin on insulinitis and β -cell destruction. This implies that at least some GAD immunity is secondary and that immunity to (pro)insulin

20 may have a more proximal role in β -cell destruction. Although NOD mouse T-cell responses to human GAD65 have been reported to be stronger and to appear earlier than those to native human insulin (5), it was found that transgenic expression of mouse proinsulin II in NOD mouse antigen presenting cells completely prevents insulinitis and diabetes (12).

25

EXAMPLE 8

Regulatory CD8 $\gamma\delta$ T cells

The inventors investigated whether aerosol insulin induced regulatory cells that could

30 inhibit the adoptive transfer of diabetes by pathogenic, effector T cells. In the classic

- 17 -

adoptive transfer model (13) (see Fig. 6), spleen cells from diabetic NOD female mice transferred intravenously to young, irradiated non-diabetic syngeneic male or female recipients cause clinical diabetes in the majority within 4 weeks. When 2×10^7 spleen cells were co-injected from older, diabetic mice with an equal number of spleen cells from aerosol ovalbumin mice, the majority of young recipients developed diabetes within 4-5 weeks; in contrast, after co-injection with spleen cells from aerosol insulin mice, only a minority developed diabetes (Fig. 1A). Diabetes incidence was suppressed by $\geq 75\%$ in six separate experiments with either splenocytes or nylon wool-non-adherent splenocytes (enriched for T cells) from aerosol insulin mice.

10

Spleen cells were then fractionated to identify the regulatory cells responsible for the suppression of diabetes transfer. Depletion and positive selection of CD4 and CD8 cells clearly showed that CD8 cells were wholly responsible for the suppression of transfer (Fig. 4B-3). Depletion of CD4 cells did not alter the ability of residual spleen cells from aerosol insulin mice to suppress transfer (Fig. 4B), and positively selected CD4 cells did not suppress transfer (Fig. 4C). On the other hand, there was no suppression by CD8-depleted spleen cells from aerosol insulin mice (Fig. 4D), whereas positively-selected CD8 cells suppressed transfer (Fig. 4E). The partial suppression by positively-selected CD8 cells, in contrast to the rapid development of diabetes after their depletion, is probably due to the inefficient recovery of CD8 cells; in this experiment, 7×10^5 purified CD8 cells were co-injected into each recipient with 2×10^7 spleen cells from diabetic mice.

T cells bearing $\gamma\delta$ receptors have been shown to have an immunoregulatory role (14-19). Interestingly, it has been reported that total peripheral blood $\gamma\delta$ cells decrease concomitantly with loss of β -cell function in humans with sub-clinical IDDM (20). To determine if the suppression of diabetes transfer that was observed was due to $\gamma\delta$ T cells, the inventors fractionated spleen cells with the anti- $\gamma\delta$ T-cell monoclonal antibody, GL3-1A (21). Depletion of $\gamma\delta$ T cells, like that of CD8 cells, completely abrogated the ability of nylon wool non-adherent spleen cells from insulin aerosol-treated mice to suppress

- 18 -

adoptive transfer of diabetes (Fig. 5A). Conversely, relatively small numbers of $\gamma\delta$ T cells from insulin aerosol-treated mice could suppress transfer. Diabetes incidence after transfer was decreased by 50% for at least 70 days when 1.4×10^5 $\gamma\delta$ T cells were co-injected with 2×10^7 spleen cells from diabetic mice (Fig. 5A). The splenic CD8 and $\gamma\delta$ T cells that suppressed diabetes transfer were one and the same, and not two interdependent populations. Thus, the ability of CD8 cells from insulin aerosol-treated mice to suppress transfer was abolished if they were first depleted of $\gamma\delta$ T cells, whereas small numbers of $\gamma\delta$ cells purified from the CD8 cells prevented transfer (Fig. 5B). A summary of the results from 11 different co-transfer experiments is presented in Fig. 3.

FACS analysis revealed that $\gamma\delta$ cells reactive with GL3 antibody constitute 1.6-2.4% of total and ~ 1% of CD8⁺ cells in the spleens of 12-16 week-old female NOD mice. These values were no different between groups of mice treated with insulin or ovalbumin aerosol. However, because of their low abundance distinct subpopulations of antigen-specific CD8 $\gamma\delta$ T cells would be difficult to distinguish this way. The higher protection with fractionated cells, for example sequentially-purified CD8 $\gamma\delta$ cells (Fig. 6), is quantitative and reflects their higher absolute number relative to that in unfractionated cells.

20

EXAMPLE 9

Aerosolization of insulin

Aerosol inhalation as a mode of insulin delivery to the mucosa was as effective as oral insulin (22, 23) in reducing diabetes incidence in the NOD mouse. The fact that it was therapeutic after the onset of insulinitis is especially relevant to the prevention of IDDM in at-risk humans with sub-clinical disease in whom the presence of circulating islet-antigen reactive antibodies and T cells is taken to reflect underlying insulinitis. Indeed, compared to humans with recently-diagnosed IDDM, NOD mice have more intense insulinitis and the majority of females progress to diabetes (10, 11, 24). Aerosol insulin had no obvious metabolic effect but induced a population of regulatory CD8 $\gamma\delta$ T cells, small numbers of which suppressed the ability of pathogenic effector T cells to adoptively transfer diabetes.

- 19 -

These antigen-induced 'suppressor' T cells protective against cell-mediated autoimmune pathology have not been previously described.

Oral tolerance has been associated with a decrease in cellular and sometimes an increase in humoral antigen-specific immunity, and with either CD8 or CD4 T cells that secrete, respectively, TGF- β or IL-4, IL-10 and TGF- β 1 (8). However, these regulatory cells have not been identified as bearing $\gamma\delta$ receptors. In NOD mice, oral tolerance to insulin was attributed to regulatory CD4 T cells (23). In accordance with the present invention CD8 $\gamma\delta$ T cells account for the regulatory cells induced by aerosol insulin.

10

EXAMPLE 10

Intranasal insulin, proinsulin or proinsulin peptide 24-36

Intranasal insulin (Fig. 1), proinsulin (Fig. 2) or proinsulin peptide 24-36 (Fig. 3).
15 Commercially available insulin at 4mg/ml, or proinsulin or proinsulin peptide 24-36 at 1-4 mg/ml in either insulin carrier solution or mouse tonicity - phosphate buffered saline, was applied in a volume of 10-20 μ l to the nostrils of unanaesthetised, restrained NOD female mice at either 28 or 56 days of age. Note that by 56 days of age all mice exhibit underlying islet inflammation (insulinitis).

20

Single doses of insulin, proinsulin or proinsulin peptide 24-36 at either 28 or 56 days of age each significantly delayed the onset and decreased the incidence of diabetes in NOD female mice, compared to control proteins ovalbumin or hen egg lysozyme (HEL, not shown). On a comparative dose basis, proinsulin and proinsulin peptide 24-36 were more
25 effective than insulin. These effects are greater with repeated doses of these proteins or peptide (not shown). In female mice pretreated with a single intranasal dose of proinsulin 24-36, whole splenocytes, and whole splenocytes depleted of CD8 but not CD4 T cells, significantly suppressed the adoptive transfer of diabetes by splenocytes from diabetic mice. Female mice were treated at 28 days of age, and then killed and their splenocytes
30 taken from adoptive co-transfers at 56 days of age (Fig. 7).

- 20 -

EXAMPLE 11

Clinical Trial of Intranasal Insulin in At-Risk Individuals

A clinical trial involves administration of intranasal insulin to at-risk but otherwise healthy
5 first-degree relatives with immune markers of IDDM, including circulating antibodies and
T cells reactive with islet autoantigens. Our subjects have at least two antibodies, to
insulin, GAD or tyrosine phosphatase IA-2, and peripheral blood T cell responses to
insulin or proinsulin peptide 24-36, and sometimes to GAD and IA-2 peptides. The
rationale is to induce mucosa-mediated immune tolerance to insulin, based on the success
10 of this approach in the NOD mouse. Commercially-available human recombinant insulin
is used, which is routinely given by subcutaneous or intravenous injection to people with
IDDM. No significant side effects have been observed in 36 high-risk subjects aged 4-30
currently entered into the Trial. The possibility of mucosal irritation exists, but this has
only been rare and then minor and transient. NOD mice treated with aerosol or intranasal
15 insulin have exhibited no clinical complications, or abnormalities at autopsy.

This trial examines the effect of intranasal insulin on the surrogate immune markers of
IDDM. The design is randomized, double-blind and placebo-controlled, with a crossover
at six months. The placebo is the carrier solution normally used for insulin. The aim is to
20 demonstrate significant effects on the levels of antibodies and T cells to insulin and other
beta cell antigens. In addition, first phase insulin release in response to an intravenous
injection of glucose, a measure of beta cell function, is monitored before, at six months
and 12 months. The crossover design gives all subjects the opportunity of treatment (an
important issue for at-risk relatives), measures if any treatment effects are sustained and
25 allows within- and between-group analyses. Treatment is administered daily for 10
consecutive days, then for two consecutive days weekly. After six months, treatment is
crossed over (from insulin to placebo, or *vice versa*).

- 21 -

The administration dose of insulin per nostril is approximately 200 μ l of the commercial 4 mg/ml solution. The placebo is the carrier solution in which the insulin is normally dissolved.

- 5 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of
- 10 said steps or features.

- 22 -

TABLE 1
Severity of insulinitis and frequency of diabetes in NOD mice
treated with aerosol protein

Protein	Insulinitis score	Diabetes frequency
Insulin	1.2 ± 0.98^1	2/32 (6.3%) ²
Ovalbumin	2.6 ± 0.92	8/32 (25%)

Mice (32/group) were given either aerosol insulin or ovalbumin for 10 consecutive days and then weekly from 28 days of age. At 105 days of age, five non-diabetic mice from each group were killed for pancreas histology. The insulinitis score is expressed as mean \pm SD.

1. The insulinitis score in insulin-treated mice was significantly reduced ($p < 0.01$, Mann-Whitney U test)
2. The diabetes frequency in insulin-treated mice significantly reduced ($p = 0.04$, Fisher's exact test)

TABLE 2
Proliferative responses of splenocytes from aerosol-treated mice

[³ H]-thymidine uptake (cpm, mean ± SD)		
Additive	Insulin aerosol	Ovalbumin aerosol
None	157 ± 28 ^a	208 ± 29 ^d
Human insulin (40 µg/ml)	134 ± 27	197 ± 82
Mouse insulin II B-chain (a 9-23) (40 µg/ml)	169 ± 80 ^b	435 ± 240 ^e
Human GAD65 (20 µg/ml)	424 ± 165 ^c	1381 ± 650 ^f
Concanavalin A (5 µg/ml)	3357 ± 812	2960 ± 494
Anti-CD3 antibody (10 µg/ml)	2221 ± 533	2643 ± 1126

c v a (p=0.001), e v d (p=0.016), f v d (p=0.001), e v b (p=0.002), f v c (p<0.0001)

Splenocytes from three mice per group were assayed in quadruplicate in HL-1 serum-free medium. Statistical comparisons (Mann-Whitney U tests) were between the twelve results for each group.

- 24 -

TABLE 3
Cytokine secretion by splenocytes from aerosol-treated mice to
40 μ g/ml of mouse insulin II B chain peptide (a 9-23)

Cytokine	Insulin aerosol	Ovalbumin aerosol
IL-2 (pg/ml)	200 \pm 15	186 \pm 27
IFN- γ (pg/ml)	368 \pm 71	423 \pm 31
IL-4 (pg/ml)	36 \pm 6	not detectable
IL-10 (pg/ml)	222 \pm 149	not detectable
TGF- β	293 \pm 131	162 \pm 41

Supernatants from replicate culture wells (Table 2) were sampled after three days incubation and assayed for cytokines.

BIBLIOGRAPHY:

1. Moses, A.C., *et al.* 1983. *Diabetes* 32:1040-1047.
2. Holt, P.G., *et al.* 1987. *Immunol. Today* 8:14-15.
3. Metzler, B., *et al.* 1993. *Inter. Immunol.* 5:1159-1165.
4. Waldo, F.B., *et al.* 1994. *Clin. Immunol. Immunopathol.* 73:30-34.
5. Kaufman, D.L., 1993. *Nature* 366:69-72.
6. Hurtenback, U., *et al.* 1989. *J. Autoimmunity* 2:151-161.
7. Hunt, P., *et al.* 1986. *J. Immunol.* 136:3994-3996.
8. Weiner, H.L., *et al.* 1994. *Annu. Rev. Immunol.* 12:809-837.
9. Tian, J., *et al.* 1996. *J. Exp. Med.* 183:1561-1567.
10. Honeyman, M.C. *et al.* 1993. *Springer Semin. Immunopathol.* 14:253-274.
11. Bach, J.F. 1994. *Endocrine Rev.* 15:516-542.
12. French, M.B., *et al.* 1997. *Diabetes* 46:34-39.
13. Wicker, L.S., *et al.* 1986. *Diabetes* (in press).
14. Kabelitz, D. 1992. *Crit. Rev. Immunol.* 11:281-303.
15. Kaufman, S.H.E., *et al.* 1993. *Proc. Natl. Acad. Sci. USA* 90:9620-9624.
16. Cardillo, F., *et al.* 1993. *Eur. J Immunol* 23:2597-2605.
17. Gorczynski, R.M. 1994. *Immunology* 81:27-35.
18. Seo, N., *et al.* 1995. *Cancer Immunol. Immunother.* 40:358-366.
19. Nakata, R., *et al.* 1995. *Immunol Immunopathol* 3:217-222.
20. Lang, F.P., *et al.* 1993. *J. Autoimmunity* 6:107-119.
21. Goodman, T., *et al.* 1989. *J. Exp. Med.* 170:1569-1581.
22. Zhang, Z.H., *et al.* 1991. *Proc. Natl. Acad. Sci. USA* 88:10252-10256.
23. Bergerot, I., *et al.* 1994. *J. Autoimmunity* 7:655-663.
24. Kikutani, H., *et al.* 1992. *Adv. Immunol.* 51:285-322.
25. Adorini, L., *et al.* 1992. *Springer Semin. Immunopathol.* 14:187-199.
26. Muir, A.D., *et al.* 1993. *Diabet. Metab. Rev.* 9:279-287.
27. Tisch, R., *et al.* 1994. *Proc. Natl. Acad. Sci. USA* 91:437-438.
28. Harrison, L.C. 1995. *Mol. Med.* 1:722-727.
29. Wells, H.G., 1911. *J. Infect. Dis.* 9:147-151.

- 26 -

30. Chen, Y., *et al.* 1994. *Science* 265:1237-1239.
31. Mordes, J.P., *et al.* 1987. *Diab. Metab. Rev.* 3:725-750.
32. Harrison, L.C. 1992. *Immunol. Today.* 13:348-352.
33. Dean, B.M., *et al.* 1986. *Diabetologia* 29:339-342.
34. Ziegler, A.G., *et al.* 1993. *Diabetologia* 36:402-408.
35. Harrison, L.C., *et al.* 1992. *J. Clin. Invest.* 89:1161-1165.
36. Rudy, G., *et al.* 1995. *Mol. Med.* 1:625-633.
37. Ziegler, A.G., *et al.* 1989. *Diabetes* 38:358-363.
38. Daniel, D., *et al.* 1986. *Proc. Natl. Acad. Sci. USA* 93:956-958.

- 27 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: AMRAD CORPORATION PTY LTD

(ii) TITLE OF INVENTION: A METHOD OF PROPHYLAXIS AND TREATMENT

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE

(B) STREET: 1 LITTLE COLLINS STREET

(C) CITY: MELBOURNE

(D) STATE: VICTORIA

(E) COUNTRY: AUSTRALIA

(F) ZIP: 3000

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL APPLICATION

(B) FILING DATE: 01-OCT-1997

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: AUSTRALIAN PROVISIONAL NO. PO2699/96

(B) FILING DATE: 01-OCT-1996

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES, DR E JOHN L

(C) REFERENCE/DOCKET NUMBER: EJH/DK

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9254 2777

(B) TELEFAX: +61 3 9254 2770

(C) TELEX: AA 31787

- 28 -

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Phe	Phe	Tyr	Thr	Pro	Lys	Thr	Arg	Arg	Glu	Ala	Glu	Asp
1				5					10			

- 29 -

CLAIMS:

1. A method of suppressing a cell-mediated autoimmune disease in a subject, said method comprising the administration as an aerosol of an effective amount of at least one antigen associated with said disease for a time and under conditions sufficient to prevent, reduce or otherwise ameliorate autoimmune pathology.
2. A method according to claim 1 wherein the autoimmune disease is insulin dependent diabetes mellitus (IDDM).
3. A method according to claim 1 wherein the autoimmune disease is slowly progressive IDDM (SPIDDM).
4. A method according to claim 1 wherein the autoimmune disease is gestational IDDM.
5. A method according to claim 1 or 2 or 3 or 4 wherein the antigen is selected from preproinsulin, proinsulin, proinsulin peptide, insulin, glutamic acid decarboxylase (GAD), tyrosine phosphatases IA-2, and derivatives or homologues thereof.
6. A method according to claim 5 wherein the proinsulin peptide is proinsulin peptide 24-36.
7. A method according to claim 5 wherein the amount of antigen administered is sufficient to induce or stimulate immunoregulatory mechanisms which are protective against cell mediated autoimmune pathology.
8. A method according to claim 7 wherein the immunoregulatory mechanism is production of suppressor T cells.

- 30 -

9. A method according to claim 8 wherein the antigen is a proinsulin peptide and suppressor T cells are CD4 T cells.
10. A method according to claim 9 wherein the suppressor T cells are CD4 $\alpha\beta$ T cells.
11. A method according to claim 7 or 8 or 9 or 10 wherein the proinsulin peptide is proinsulin peptide 24-36.
12. A method according to claim 8 wherein the antigen is insulin and the suppressor T cells are CD8 T cells.
13. A method according to claim 12 wherein the suppressor T cells are CD8 $\gamma\delta$ T cells.
14. A method according to claim 5 wherein more than one antigen is administered simultaneously or sequentially.
15. A method according to claim 14 wherein a proinsulin peptide is administered simultaneously or sequentially with one or more of insulin, GAD, tyrosine phosphatase IA-2, preproinsulin or proinsulin.
16. A method according to claim 14 wherein proinsulin or a derivative or homologue thereof is administered simultaneously or sequentially with a disease suppressing peptide comprising the proinsulin 24-36 sequence

FFYTPKTRREAED [SEQ ID NO:1].

17. A method for the prophylaxis or treatment of IDDM, SPIDDM or gestational IDDM comprising the administration as an aerosol of one or more of proinsulin, proinsulin peptide, preproinsulin, insulin, GAD or tyrosine phosphatase IA-2, or derivative or homologue thereof for a time and under conditions sufficient to prevent,

- 31 -

reduce or otherwise ameliorate autoimmune pathology of IDDM, SPIDDM or gestational IDDM.

18. A method according to claim 17 wherein the proinsulin peptide is proinsulin peptide 24-36

19. A method according to claim 17 wherein a proinsulin peptide is administered simultaneously or sequentially with one or more of insulin, GAD, tyrosine phosphatase IA-2, proinsulin or preproinsulin.

20. A method according to claim 17 wherein proinsulin or a derivative or homologue thereof is simultaneously or sequentially administered with a disease suppressing peptide comprising the proinsulin 24-36 sequence

FFYTPKTRREAED [SEQ ID NO:1].

21. A method according to any one of the preceding claims wherein the antigen or combination of antigens are delivered by aerosol form at a rate of from 1 to about 20 litres/min.

22. A method according to claim 20 wherein the amount of antigen administration is from about 0.1 μ g to about 5 mg.

23. A composition comprising proinsulin or a derivative or homologue thereof in a form suitable for aerosol administration and one or more pharmaceutically acceptable carriers and/or diluents.

24. A composition according to claim 22 further comprising insulin.

25. A composition according to claim 22 further comprising proinsulin peptide 24-36.

- 32 -

26. A composition according to claim 22 further comprising a disease suppressing peptide comprising the proinsulin 24-36 sequence

FFYTPKTRREAED [SEQ ID NO:1].

27. An agent for the prophylaxis and treatment of IDDM,,SPIDDM or gestational IDDM wherein said agent induces or stimulates immunoregulatory mechanisms, said agent comprising proinsulin or a derivative or homologue thereof in a form suitable for aerosol administration and one or more pharmaceutically acceptable carriers and/or diluents.

28. An agent according to claim 26 wherein said immunoregulatory mechanism is production of suppressor T cells.

29. An agent according to claim 27 further comprising one or more of insulin, proinsulin peptide 24-36 and a disease suppressing peptide comprising the proinsulin 24-36 sequence

FFYTPKTRREAED [SEQ ID NO:1].

30. Use of proinsulin or a derivative or homologue thereof in the manufacture of a medicament for the prophylaxis or treatment of IDDM, SPIDDM or gestational IDDM.

31. Use according to claim 30 further comprising the use of one or more insulin, proinsulin peptide 24-36 and a disease suppressing peptide comprising the proinsulin 24-36 sequence

FFYTPKTRREAED [SEQ ID NO:1].

1/9




Fig.1

2/9




Fig.2

3/9

INTRANASAL HUMAN PROINSULIN aa24-36 (40ug) AT 56 DAYS OF AGE
 DELAYS DIABETES ONSET




Fig.3

4/9




Fig. 4A




Fig. 4B

5/9




Fig.4C




Fig.4D

6/9




Fig.4E

7/9




Fig.5A




Fig.5B

8/9

CD 8 $\gamma\delta$ T CELLS FROM INSULIN AEROSOL-TREATED MICE
BLOCK ADOPTIVE TRANSFER OF DIABETES




Fig.6

9/9

INTRANASAL HUMAN PROINSULIN aa24-36 INDUCES CD4⁺ T CELLS THAT
SUPPRESS ADOPTIVE TRANSFER OF DIABETES




Fig. 7

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 97/00654

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : A61K 38/28, 39/00, 38/46, 38/51																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) DERWENT AND CHEM ABS keywords as below																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched FILE MEDLINE																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT WPAT database, KEYWORDS: [(preproinsulin or insulin or proinsulin () peptide# or proinsulin or glutamic()acid() decarboxylase or gad or tyrosine() phosphatase) and aerosol] or [proinsulin and mellitus] or [aerosol# and autoantigen#] CHEM ABSTRACTS AND FILE MEDINE databases, KEYWORDS: Same as above FFYTPKTRREAED/SQSP																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	PATHOLOGIE BIOLOGIE, April 1996, VOLUME 44 No 4, Pages 235-240 (Valensi, P et al.) "Effect of insulin concentration on bioavailability during nasal spray administration".																					
X	CELLULAR IMMUNOLOGY, (1996), VOLUME 171 No 1, Pages 111-119 (Al-SABBAGH, A et al.)	1, 21, 22																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier document but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 25 November 1997		Date of mailing of the international search report 03 DEC 1997																				
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer <i>Arati Sardana</i> ARATI SARDANA Telephone No.: (02) 6283 2627																				

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00654

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	"Antigen-driven peripheral immune tolerance; suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen".	
X	THE JOURNAL OF EXPERIMENTAL MEDICINE, December 1996, VOLUME 184, No 6, pages 2167-2174 (HARRISON, LEONARD C et al.) "Aerosol insulin induces regulatory CD8Y8T cells that prevent murine insulin-dependant diabetes".	1-31
X	WO 91/08760 A (BRIGHAM AND WOMEN'S HOSPITAL) Published 27 June 1991 (27.7.91) See whole document	1-31
X	WO 91/09619 A (INTERNATIONAL INSTITUTE OF CELLULAR AND MOLECULAR PATHOLOGY) Published 11 July 1991 (11.7.91) See whole document	1-31
X	WO 95/24183 A (INHALE THERAPEUTIC SYSTEMS) Published 14 September 1995 (14.9.95) See whole document	1-31
X	WO 96/01846 A (TRUSTEES OF DARTMOUTH COLLEGE) Published 25 January 1996 (25.1.96) See whole document	1-31
X	WO 86/05496 A (NORDISK GENTOFTE A/S) Published 25 September 1986 (25.9.86)	1-31
X	US 4 654 324 A (ELI LILLY AND COMPANY) Published 31 March 1987 (31.3.87)	30
X	US 4 652 548 A (ELI LILLY AND COMPANY) Published 24 March 1987 (24.3.87)	31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/AU 97/00654

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	9109619	AU	69626/91	CA	2015515	DE	69007799
		EP	508993	JP	3227942		
WO	9524183	AU	17449/95	EP	748213	ZA	9501883
WO	9601846	AU	29673/95	AU	30947/95	CA	2194548
		CA	2194550	EP	788512	EP	773790
WO	8605496	AU	56226/86	AU	56227/86	DE	3673737
		DE	3687500	EP	216832	EP	216833
		JP	62502196	JP	62502538	US	5028586
		US	5157021				
US	4 654 324	AU	87595/82	AU	552054	CA	1176160
		FR	2511866	GB	2104380	JP	58046023
US	4 652 548	AU	87597/82	AU	551734	DE	3232035
		FR	2511868	GB	2104381	JP	58046026
		NL	8203313				
WO	9108760	AU	69791/91	CA	2070281	EP	506785
		JP	5504341	US	5 571 499	DE	3854741
END OF ANNEX							